PIK3CA and urinary bladder cancer: We used this bladder cancer specific RAS-BC assay together with similar assays that we developed previously for FGFR3 and PIK3CA[53], [55], to investigate the frequency of these mutations in an unselected series of primary tumors of 257 patients representing all stages and grades and 184 successive recurrent bladder tumors of 54 patients.